GLP‑1 market splits
Indian manufacturers launched roughly 26 generic semaglutide brands in weeks, pressuring Eli Lilly’s share while Novo Nordisk has held up better in that market. (cnbc.com) Separately, a large genetic study linked common variants in GLP1R and GIPR to both weight loss and side effects on GLP‑1 drugs, suggesting clinical responses may be predictable and that payers could move toward more targeted prescribing. (news-medical.net, euronews.com)
India’s weight-loss drug market just split in two directions at once: cheap copies are arriving fast, and the science is getting more personalized at the same time. In March, Eli Lilly’s share of India’s market for these drugs fell to 56% from 61%, while Novo Nordisk held at 25% even as local companies launched 26 semaglutide brands in a few weeks. (cnbc.com) Semaglutide is the ingredient in Novo Nordisk’s Ozempic and Wegovy, and tirzepatide is the ingredient in Eli Lilly’s Mounjaro and Zepbound. India’s generic wave hits semaglutide directly because manufacturers can copy that molecule there, while tirzepatide still has less direct low-price competition. (cnbc.com) That helps explain the odd market picture. Novo Nordisk is facing a flood of semaglutide rivals but kept its share steady in March, while Eli Lilly, which had been the market leader, lost ground even without 26 direct tirzepatide copycats showing up beside it. (cnbc.com) One reason is that India is not just a patent story. It is also a pricing story, a doctor-habit story, and a supply story, and Reuters reported the market-share data through Pharmarack, which tracks what is actually moving through pharmacies rather than what global investors assume should happen. (cnbc.com) Now the second split: not every patient responds to these drugs the same way, and a new Nature study looked for a reason in DNA. Researchers analyzed 27,885 people who had used glucagon-like peptide-1 drugs and found common genetic variants tied to both extra weight loss and a higher chance of nausea or vomiting. (nature.com, nature.com) The key genes were GLP1R and GIPR, which are the instruction codes for the drug targets themselves. If the drug is like a key and the receptor is like a lock, this study suggests some people are born with slightly different locks, and those small differences can change both the benefit and the side effects. (nature.com, euronews.com) The GLP1R signal showed up across glucagon-like peptide-1 treatments, while the GIPR side-effect signal was concentrated in people using tirzepatide, which hits both the glucagon-like peptide-1 pathway and the glucose-dependent insulinotropic polypeptide pathway. That makes the biology line up with the drug design instead of looking like a random statistical blip. (nature.com) The practical change is not that doctors will start swabbing cheeks next week. The practical change is that insurers, employers, and drugmakers now have fresh evidence that a one-size-fits-all obesity-drug market may waste money on some patients and overload others with side effects. (news-medical.net, nature.com) Put those two developments together and the market starts to look less like one giant winner-take-all category. India is showing how fast price competition can turn semaglutide into a crowded shelf product, while genetics is pointing toward a future where the premium drugs may be sold on “which patient” rather than just “which brand.” (cnbc.com, nature.com) That is why the pressure is landing differently on Eli Lilly and Novo Nordisk right now. One fight is about who can defend margins when copies get cheap, and the next fight may be about who can prove, with data, that a specific patient should get one drug instead of another. (cnbc.com, euronews.com)
